Elucigene Diagnostics

Elucigene Diagnostics is a UK-based company specializing in genetic testing solutions for healthcare professionals, focused on delivering precise diagnostics for genetic disorders and conditions using advanced molecular biology techniques. Founded in 1994 and headquartered in Manchester, UK, Elucigene Diagnostics provides innovative genetic testing solutions. The company was acquired by Yourgene Health plc in April 2019 for GBP 9. 2 million, marking a significant pivot in its business operations.

Elucigene has successfully completed 2 deals, with their most recent deal occurring on April 17, 2019. The firm does not have any known parent companies or subsidiaries, and no previous founders' information is available. Elucigene specializes in developing and providing advanced genetic testing solutions tailored for the healthcare sector. Their core offerings include diagnostic tests that employ cutting-edge molecular biology techniques to accurately identify genetic disorders and conditions.

These products cater to healthcare professionals, such as hospitals and laboratories, enabling timely and precise diagnoses for patients suspected of having genetic diseases. Elucigene focuses on solutions for inherited conditions and specific cancer types, thus enhancing patient outcomes and supporting personalized medicine. The company's products are available in various regions, including Europe, North America, and parts of Asia, serving a diverse clientele comprising healthcare providers, research institutions, and genetic laboratories. In the most recent year of 2022, Elucigene generated revenue of GBP 397.

2 mn, with an EBITDA of GBP 0 for 2023. The company operates primarily through B2B transactions, supplying genetic testing products to hospitals, clinics, and diagnostic laboratories. Their revenue model emphasizes direct sales of diagnostic tests designed for reliable and efficient identification of genetic conditions, complemented by strategic partnerships with healthcare providers to foster repeat business and collaborative research initiatives. Elucigene Diagnostics aims to expand its product line with new genetic testing solutions set to launch in the coming years.

The company is focused on entering additional markets, targeting regions in Asia and North America for expansion by 2025. The recent acquisition by Yourgene Health plc for GBP 9. 2 million will facilitate these growth strategies, providing the necessary capital to enhance product development and market reach. The acquisition deal was completed in April 2019, reinforcing Elucigene's commitment to advancing genetic testing in the medical field.